Resource Library
Our leadership in TPD is propelling the field forward.
Related Resources
May 31, 2022
STAT3 degraders inhibit Th17 development and cytokine production resulting in profound inhibition of collagen-induced autoimmune murine arthritis
European Alliance of Associations for Rheumatology (EULAR) 2022 Annual Congress
May 17, 2022
Kinetics of IRAK4 Degradation and Impact on Functional Response in Circulating Immune Cells and Skin Cell Subsets
Society for Investigative Dermatology (SID) 2022 Annual Meeting
May 10, 2022
Non-Clinical Safety Considerations when Developing Targeted Protein Degraders
Applied Pharmaceutical Toxicology (APT) 2022
April 27, 2022
Drugging Tissue Restricted E3 Ligases for TPD-based Precision Medicine
2nd Annual Ligase Targeting Drug Development Summit
April 26, 2022
Chemically Harnessing Novel E3 Ligases Biology for Next-generation TPD Therapeutics
2nd Annual Ligase Targeting Drug Development Summit
October 28, 2021
Considerations for E3 Ligase Pairing and Screening of Immune-Inflammation Targets
4th Annual TPD Summit
October 27, 2021
Understanding PK/PD for Development of STAT3 Degraders in Oncology Indications
4th Annual TPD Summit
Other
Read More
September 15, 2021
Inventing New Medicines with Targeted Protein Degradation
Undruggable Leaders Forum
May 26, 2021
Drugging Tissue-Restricted E3 Ligases
Ligase Targeting Drug Development Summit
February 16, 2021
Targeted Protein Degradation in Oncology and Beyond
2nd Annual North American Protein Degradation Congress